Miprosed (Midazolam)

Midazolam, the active ingredient in Miprosed, is a benzodiazepine presented as an oral formulation for oral use. It is employed to manage anxiety, provide procedural sedation, treat insomnia, and control seizures in adult patients.

GNH USA supplies Miprosed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides full regulatory documentation for import and distribution. Our logistics network ensures timely delivery to healthcare facilities across multiple continents globally.

Midazolam acts on the central nervous system to produce anxiolytic, sedative, hypnotic, and anticonvulsant effects.

- Anxiety: reduces acute anxiety symptoms in adults. - Procedural sedation: provides short‑acting sedation for diagnostic or minor surgical procedures. - Insomnia: induces sleep onset and maintenance in patients with severe insomnia. - Seizure control: terminates acute seizure activity and helps prevent recurrence.

Midazolam may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Drowsiness - Dizziness - Impaired coordination - Memory impairment - Mild respiratory depression - Nausea

Serious or Rare Side Effects: - Severe respiratory depression - Hypotension - Paradoxical agitation or aggression - Allergic reactions including anaphylaxis - Cardiac depression - Withdrawal seizures

When prescribing or dispensing Midazolam, several safety considerations are recommended.

- Dose adjustment: reduce dose in elderly or hepatic impairment patients. - Avoid abrupt discontinuation: taper to prevent withdrawal seizures. - Use caution with respiratory disease: monitor ventilation closely. - Contraindicated in patients with known hypersensitivity to benzodiazepines. - Pregnancy: assess risk‑benefit, limited data available. - Store at ambient temperature: keep below 25°C, protect from moisture and light in original container.

Midazolam interacts with several drug classes; awareness helps prevent additive effects.

Major Interactions (Avoid): - Opioids: combined use may cause profound respiratory depression. - Barbiturates: additive central nervous system depression. - Antifungals (e.g., ketoconazole): increase midazolam plasma concentrations.

Moderate Interactions (Monitor Closely): - Macrolide antibiotics (e.g., erythromycin): may raise plasma levels. - CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - Alcohol: enhances sedative effect.